Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Has announcements × fludarabine × Clear all

Phase

Phase 3 3 Phase 2 3 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Interventions

pembrolizumab 3 selpercatinib 2 obinutuzumab 2 ibrutinib 2 Rituximab 2 Nivolumab 2 Midazolam 2 Ipilimumab 2 Crizotinib 2 zanubrutinib 1 venetoclax 1 trametinib 1 toripalimab 1 tocilizumab 1 tazemetostat 1 tagraxofusp 1 sotorasib 1 sacituzumab govitecan 1 romiplostim 1 revumenib 1 repotrectinib 1 prednisolone phosphate 1 prednisolone acetate 1 pralsetinib 1 polatuzumab vedotin 1 pirtobrutinib 1 olutasidenib 1 naxitamab 1 mobocertinib 1 lorlatinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02614066 2024-11-19

ZUMA-3

Gilead Sciences

Phase 1/2 Completed

125 enrolled 27 charts 2 FDA

Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡